Side-by-Side Comparison

Tirzepatide vs Semaglutide

Dosing, half-life, mechanism, benefits, and safety — side by side.

Tirzepatide

FDA Approved

Dual GLP-1/GIP receptor agonist with superior weight loss efficacy

Half-Life

~5 days

Route

Dose

2.5-15 mg Weekly

4813.45 Da

Full Tirzepatide research guide →

Semaglutide

FDA Approved

GLP-1 receptor agonist for weight loss and type 2 diabetes management

Half-Life

~7 days

Route

Dose

0.25-2.4 mg Weekly

4113.58 Da

Full Semaglutide research guide →

Quick Reference

	Tirzepatide	Semaglutide
Category	N/A	N/A
Route	SC	SC
Typical Dose	2.5-15 mg Weekly	0.25-2.4 mg Weekly
Frequency	Weekly	Weekly
FDA Approved	Yes	Yes
WADA Status	Not banned	Not banned

⏱ Pharmacokinetics

	Tirzepatide	Semaglutide
Half-Life	~5 days	~7 days
Research Status	N/A	N/A
CAS Number	2023788-19-2	910463-68-2

Molecular

	Tirzepatide	Semaglutide
Molecular Weight	4813.45	4113.58
Molecular Formula	C225H348N48O68	C187H291N45O59
Sequence Length	180 aa	180 aa
Mechanism	Dual GLP-1/GIP receptor agonist for enhanced metabolic effects	GLP-1 receptor agonist that regulates appetite and glucose metabolism

Key Benefits

	Tirzepatide	Semaglutide
Benefits	Superior weight loss vs GLP-1 alone; Enhanced glycemic control; Dual hormone pathway activation; Cardiovascular protection; Improved metabolic parameters; Dual agonist (GLP-1; GIP); Superior weight loss vs Semaglutide	Significant weight loss; Blood sugar control; Reduced cardiovascular risk; Appetite suppression; Improved insulin sensitivity; GLP-1 agonist; Significant weight loss; Blood sugar control.

Safety & Warnings

	Tirzepatide	Semaglutide
Safety Note	FDA approved. Most common side effects are GI-related and typically mild to moderate.	FDA approved for diabetes and obesity. Common side effects include nausea, vomiting, and diarrhea.
Side Effects	Interaction; Interaction; GI events; Discontinuation; Nausea; Vomiting; Rare pancreatitis/gallbladder disease; Constipation	Constipation; Interaction; Nausea; Diarrhea; Rare pancreatitis or thyroid risk; Interaction; GI adverse events; Discontinuation (GI)
Athlete Warning	Not WADA banned - safe for competitive athletes when used under medical supervision	Not WADA banned - safe for competitive athletes when used under medical supervision

Which should you choose?

Semaglutide has a longer half-life (~~7 days) than Tirzepatide (~~5 days), which can mean less frequent dosing.

Tirzepatide vs Semaglutide — FAQ

Which has a longer half-life: Tirzepatide or Semaglutide?

Tirzepatide has a half-life of ~~5 days while Semaglutide has a half-life of ~~7 days. A longer half-life generally means less frequent dosing and more stable levels.

Can I stack Tirzepatide and Semaglutide together?

Whether Tirzepatide and Semaglutide can be stacked depends on their mechanisms and receptor targets. Use the stack compatibility checker to analyze synergies and conflicts before combining any peptides.

Which is better: Tirzepatide or Semaglutide?

There is no universal "better" peptide — it depends on your goal. Tirzepatide is Dual GLP-1/GIP receptor agonist for enhanced metabolic effects. Semaglutide is GLP-1 receptor agonist that regulates appetite and glucose metabolism. Choose based on your primary goal and research profile.

Compare any two peptides Check stack compatibility

More Comparisons

BPC-157 vs TB-500

Compare side-by-side →

Retatrutide vs Tirzepatide

Compare side-by-side →

Semaglutide vs Retatrutide

Compare side-by-side →

Ipamorelin vs Sermorelin

Compare side-by-side →

CJC-1295 vs Sermorelin

Compare side-by-side →

MK-677 vs Ipamorelin

Compare side-by-side →

GHK-Cu vs AHK-Cu

Compare side-by-side →

Selank vs Semax

Compare side-by-side →

MOTS-c vs NAD+

Compare side-by-side →

PT-141 vs Melanotan-II

Compare side-by-side →

Tesamorelin vs CJC-1295

Compare side-by-side →

HGH vs MK-677

Compare side-by-side →

Semaglutide vs Liraglutide

Compare side-by-side →